Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies and commercial real estate assets.The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.
